NEW YORK (GenomeWeb News) — Pfizer Canada has given CA$500,000 ($440,000) to a Canadian research project studying the pharmacogenomics of pediatric drug toxicity, the company said today.
The project, Genotype-Specific Approaches to Therapy in Childhood initiative, or GATC, plans to study DNA from children who have experienced adverse drug reactions in hopes of identifying biomarkers linked to severe drug toxicity.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.